EGRP News Flash - June 6, 2008
Funding Opportunity Announcements: Biomarkers of Infection-Associated Cancers
On behalf of the National Cancer Institute (NCI) and the National Institute of Dental and Craniofacial Research (NIDCR), NCI's Epidemiology and Genetics Research Program (EGRP) announces two funding opportunity announcements (FOAs), that encourage the submission of Research Project Grant (R01) applications and Exploratory/Developmental Grant (R21) applications from institutions and organizations that propose to identify biomarkers for cancers where the etiology of the disease is attributed to infectious agents.
The objectives of these FOAs are to foster research to increase our knowledge of infectious agent-associated malignancies and identify those who are at increased risk of developing cancer among infected individuals and to detect early stage cancers in this population. The long-term goal of these FOAs is to encourage research that will increase our knowledge of infectious agent-associated malignancies and utilization of molecular profiles in early detection, risk assessment, and prevention of cancer. Listed below, but not limited to, are several programmatic areas in need of support for developing molecular signatures for infectious agent-associated cancers.
- Molecular profiles of normal, precancerous, and cancerous lesions following infection and of body fluids from infected individuals.
- Evaluation of these molecular profiles for use in gaining a better understanding of the role of infectious agents in cancer development and use in early detection, risk assessment, and prevention of cancer.
Awards issued under these FOAs are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received.
R01 applicants requesting $500,000 or more in direct costs for any year (excluding consortium F&A costs) must carry out the following steps:
- Contact the appropriate NIH institute or center (IC) program staff member(s) at least 6 weeks before submitting the application, i.e., as plans are being developed for the study;
- Obtain agreement from the IC staff member that the IC will accept the application for consideration for award; and
- Include a cover letter with the application that identifies the staff member and IC that agreed to accept assignment of the application.
The total project period for R21 applications submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year. The R21 is not renewable. Both FOAs expire May 8, 2011. Standard application submission and receipt dates apply.
The NCI cosponsors for these FOAs include the Division of Cancer Prevention and the Division of Cancer Biology. Please refer to the FOAs for the scientific contacts.
Access the NIH GUIDE FOR GRANTS AND CONTRACTS: